| 000 | 01771 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515030024.0 | ||
| 264 | 0 | _c20060905 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0006-8993 | ||
| 024 | 7 |
_a10.1016/j.brainres.2006.04.019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Xiaoqun | |
| 245 | 0 | 0 |
_aRepeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bBrain research _cJun 2006 |
||
| 300 |
_a207-10 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic Agents _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBrain-Derived Neurotrophic Factor _xgenetics |
| 650 | 0 | 4 |
_aCocaine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine Uptake Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aGene Expression Regulation _xdrug effects |
| 650 | 0 | 4 |
_aLevodopa _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Binding _xdrug effects |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-fos _xgenetics |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aSubthalamic Nucleus _xdrug effects |
| 650 | 0 | 4 |
_aTritium _xpharmacokinetics |
| 700 | 1 | _aAndren, Per E | |
| 700 | 1 | _aSvenningsson, Per | |
| 773 | 0 |
_tBrain research _gvol. 1095 _gno. 1 _gp. 207-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.brainres.2006.04.019 _zAvailable from publisher's website |
| 999 |
_c16322635 _d16322635 |
||